Melatonin: Therapeutic and clinical utilization

International Journal of Clinical Practice

Volumn 61, Issue 5, 2007, Pages 835-845

  Altun, A ^a   Ugur Altun, B ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN;

ANTERIOR HYPOTHALAMUS; ANTICONVULSANT ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BLOOD PRESSURE REGULATION; CELL PROTECTION; CERVICAL GANGLION; CIRCADIAN RHYTHM; CLUSTER HEADACHE; CORONARY ARTERY ATHEROSCLEROSIS; CYTOKINE PRODUCTION; DRUG POTENCY; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART PROTECTION; HORMONAL REGULATION; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; IMMUNOREGULATION; JET LAG; KIDNEY DISEASE; MIGRAINE; NEUROMODULATION; OPTIC NERVE; PINEAL BODY; PREGANGLIONIC NERVE CELL; PRIORITY JOURNAL; RETINA GANGLION CELL; REVIEW; SLEEP DISORDER; THALAMUS MIDLINE NUCLEUS; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARDIOVASCULAR DISEASES; CIRCADIAN RHYTHM; HUMANS; IMMUNE SYSTEM; IMMUNE SYSTEM DISEASES; JET LAG SYNDROME; MELATONIN; MENTAL DISORDERS; NEOPLASMS; NERVOUS SYSTEM DISEASES; SLEEP INITIATION AND MAINTENANCE DISORDERS; WORK SCHEDULE TOLERANCE;

EID: 34247151073     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01191.x     Document Type: Review

References (128)

1. Witt-Enderby PA, Bennett J, Jarzynka MJ, Firestine S, Melan MA. Melatonin receptors and their regulation: biochemical and structural mechanisms. Life Sci 2003; 72: 2183-98.
2. Scheer FA, Czeisler CA. Melatonin, sleep and circadian rhythms. Sleep Med Rev 2005; 9: 5-9.
3. Cardinali DP, Bursco LI, Floret SP, Furio AM. Melatonin in sleep disorders and jet lag. Neuro Endocrinol Lett 2002; 23 (Suppl. 1): 9-13.
4. Buscemi N, Vandermeer B, Pandya R et al. Melatonin for treatment of sleep disorders. Evid Rep Technol Assess (Summ) 2004; 108: 1-7.
5. Herxheimer A. Jet lag. Clinical Evid 2004; 12: 2394-400.
6. Beaumont M, Batejat D, Pierard C et al. Caffeine or melatonin effects on sleep and sleepiness after rapid eastward transmeridian travel. J Appl Physiol 2004; 96: 50-8.
7. Zhdanova IV. Melatonin as a hypnotic: pro. Sleep Med Rev 2005; 9: 51-65.
8. Brzezinski A, Vangel MG, Wurtman RJ et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9: 41-50.
9. Santhi N, Duffy JF, Horowitz TS, Czeisler CA. Scheduling of sleep/darkness affects the circadian phase of night shift workers. Neurosci Lett 2005; 384: 316-20.
10. van den Heuvel CJ, Ferguson SA, Macchi MM, Dawson D. Melatonin as a hypnotic: con. Sleep Med Rev 2005; 9: 71-80.
11. Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev 2005; 9: 25-39.
12. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9: 11-24.
13. Jonas M, Garfinkel D, Zisapel N, Laudon M, Grossman E. Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press 2003; 12: 19-24.
14. Zeman M, Dulkova K, Bada V, Herichova I. Plasma melatonin concentrations in hypertensive patients with the dipping and non-dipping blood pressure profile. Life Sci 2005; 76: 1795-803.
15. Esquifino AI, Pandi-Perumal SR, Cardinali DP. Circadian organization of the immune response: a role for melatonin. Clin Appl Immunol Rev 2004; 4: 423-33.
16. Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr Top Med Chem 2002; 2: 167-80.
17. Maestroni CJM. The immunoneuroendocrine role of melatonin. J Pineal Res 1993; 14: 1-10.
18. Liu F, Ng TB, Fung MC. Pineal indoles stimulate the gene expression of immunomodulating cytokines. J Neural Transm 2001; 108: 397-405.
19. Garcia-Maurino S, Pozo D, Calvo JR, Guerrero JM. Correlation between nuclear melatonin receptor expression and enhanced cytokine production in human lymphocytic and monocytic cell lines. J Pineal Res 2000; 29: 129-37.
20. Molinero P, Soutto M, Benot S, Hmadcha A, Guerrero JM. Melatonin is responsible for the nocturnal increase observed in serum and thymus of thymosin and a1 and thymulin concentrations: observations in rats and humans. J Neuroimmunol 2000; 103: 108-88.
21. Sainz RM, Mayo JC, Reiter RJ, Antolin I, Esteban MM, Rodriguez C. Melatonin regulates glucocorticoid receptor: an answer to its antiapoptic action in thymus. FASEB J 1999; 13: 1547-56.
22. Withyachumnarnkul B, Nonaka KO, Santana C, Attia AM, Reiter RJ. Interferon-gamma modulates melatonin production in rat pineal glands in organ culture. J Interferon Res 1990; 10: 403-11.
23. Sutherland ER, Martin RJ, Ellison MC, Kraft M. Immunomodulatory effects of melatonin in asthma. Am J Respir Crit Care Med 2002; 166: 1055-61.
24. Sulli A, Maestroni GJ, Villaggio B et al. Melatonin serum levels in rheumatoid arthritis. Ann N Y Acad Sci 2002; 966: 276-83.
25. Cutolo M, Maestroni GJ. The melatonin-cytokine connection in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 1109-11.
26. Cutolo M, Masi AT. Circadian rhythms and arthritis. Rheum Dis Clin North Am 2005; 31: 115-29.
27. Maestroni GJ, Cardinali DP, Esquifino AI, Pandi-Perumal SR. Does melatonin play a disease-promoting role in rheumatoid arthritis? J Neuroimmunol 2005; 158: 106-11.
28. Sutherland ER, Ellison MC, Kraft M, Martin RJ. Elevated serum melatonin is associated with the nocturnal worsening of asthma. J Allergy Clin Immunol 2003; 112: 513-7.
29. Campos FL, da Silva-Junior FP, de Bruin VM, de Bruin PF. Melatonin improves sleep in asthma: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2004; 170: 947-51.
30. Cagnoni ML, Lombardi A, Cerinic MC, Dedola GL, Pignone A. Melatonin for treatment of chronic refractory sarcoidosis. Lancet 1995; 34: 1229-30.
31. Calvo JR, Guerrero JM, Osuna C, Molinero P, Carrillo-Vico A. Melatonin triggers Crohn's disease symptoms. J Pineal Res 2002; 32: 277-8.
32. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anti-cancer agent: cellular, biochemical and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2002; 2: 113-32.
33. Sauer LA, Dauchy RT, Blask DE. Polyunsaturated fatty acids, melatonin and cancer progression. Biochem Pharmacol 2001; 61: 1455-62.
34. Lissoni P. Is there a role for melatonin in supportive care? Support Care Cancer 2002; 10: 110-6.
35. Lissoni P, Malugani F, Brivio F et al. Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study. Neuro Endocrinol Lett 2003; 24: 259-62.
36. Lissoni P, Chilelli M, Villa S, Cerizza L, Tancini G. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res 2003; 35: 12-5.
37. Ugur-Altun B, Altun A. Melatonin and woman. In: Pandi-Perumal SR, Cardinali DP, eds. Melatonin: From Molecules to Therapy, chapter 44. NewYork: Nova Science Publishers, 2006: (in press).
38. Sanchez-Barcelo EJ, Cos S, Mediavilla D, Martinez-Campa C, Gonzalez A, Alonso-Gonzalez C. Melatonin-estrogen interactions in breast cancer. J Pineal Res 2005; 38: 217-22.
39. Vijayalaxmi, Thomas CR, Reiter RJ, Herman TS. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002; 20: 2575-601.
40. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004; 3: 213-4.
41. Reiter RJ, Tan DX, Sainz RM, Mayo JC. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002; 54: 1299-321.
42. Lissoni P, Paolorossi F, Tancini G et al. Is there a rold for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996; 32A: 1340-3.
43. Persson C, Glimelius B, Ronnelid J, Nygren P. Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study. Nutrition 2005; 21: 170-8.
44. Lercher P, Stoschitzky K, Sakotnik A, Liebmann P, Klein W. Melatonin in patients with coronary artery disease, hypertensive heart disease and dilated cardiomyopathy. Atherosclerosis 2000; 151; 203.
45. Rapoport SI, Shatalova AM, Malinovskaia NK, Vettenberg L. Melatonin production in hypertensive patients. Klin Med (Mosk) 2000; 78: 21-4.
46. Lusardi P, Piazza E, Fogari R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. Br J Clin Pharmacol 2000; 49: 423-7.
47. Escames G, Khaldy H, Leon J, Gonzalez L, Acuna-Castroviejo D. Changes in iNOS activity, oxidative stress and melatonin levels in hypertensive patients treated with lacidipine. J Hypertens 2004; 22: 629-35.
48. Scheer FA, Van Montfrans GA, van Someren EJ, Mairuhu G, Buijs RM. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 2004; 43: 192-7.
49. Yaprak M, Altun A, Vardar A, Aktoz M, Ciftci S, Ozbay G. Decreased nocturnal synthesis of melatonin in patients with coronary artery disease. Int J Cardiol 2003; 89: 103-7.
50. Girotti L, Lago M, Ianovsky O et al. Low urinary 6-sulphatoxymelatonin levels in patients with coronary artery disease. J Pineal Res 2000; 29: 138-42.
51. Sakotnik A, Liebmann PM, Stoschitzky K et al. Decreased melatonin synthesis in patients with coronary artery disease. Eur Heart J 1999; 20: 1314-7.
52. Marktl W, Brugger P, Herold M. Melatonin and coronary heart disease. Wiener Klin Wochenschr 1997; 109: 747-9.
53. Brugger P, Marktl W, Herold M. Impaired nocturnal secretion of melatonin in coronary heart disease. Lancet 1995; 345: 1408.
54. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez M, Ferrer-Hita J, Vargas M, Reiter RJ. Elevated levels of oxidized low-density lipoprotein and impaired nocturnal synthesis of melatonin in patients with myocardial infarction. Atherosclerosis 2005; 180: 101-5.
55. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia MJ, Sanchez J, Marrero F, de Armas-Trujillo D. Decreased nocturnal melatonin levels during acute myocardial infarction. J Pineal Res 2002; 33: 248-52.
56. Tutuncu NB, Batur MK, Yildirir A et al. Melatonin levels decrease in type 2 diabetic patients with cardiac autonomic neuropathy. J Pineal Res 2005; 39: 43-9.
57. Cavallo A, Daniels SR, Dolan LM, Bean JA, Khoury JC. Blood pressure-lowering effect of melatonin in type 1 diabetes. J Pineal Res 2004; 36: 262-6.
58. Cavallo A, Daniels SR, Dolan LM, Khoury JC, Bean JA. Blood pressure response to melatonin in type 1 diabetes. Pediatr Diabetes 2004; 5: 26-31.
59. O'Brien IA, Lewin IG, O'Hare JP, Arendt J, Corrall RJ. Abnormal circadian rhythm of melatonin in diabetic autonomic neuropathy. Clin Endocrinol (Oxf) 1986; 24: 359-64.
60. Girotti L, Lago M, Ianovsky O et al. Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure. Endocrine 2003; 22: 245-8.
61. Sandyk R, Awerbuch GI. The relationship between melatonin secretion and serum cholesterol in patients with multiple sclerosis. Int J Neurosci 1994; 76: 81-6.
62. Rindone JP, Achacoso R. Effect of melatonin on serum lipids in patients with hypercholesterolemia: a pilot study. Am J Ther 1997; 4: 409-11.
63. Pittalis S, Lissoni P, Giani L et al. Effect of a chronic therapy with the pineal hormone melatonin on cholesterol levels in idiopathic hypercholesterolemic patients. Recenti Prog Med 1997; 88: 401-2.
64. Altun A, Yaprak M, Aktoz M, Vardar A, Betul UA, Ozbay G. Impaired nocturnal synthesis of melatonin in patients with cardiac syndrome X. Neurosci Lett 2002; 327: 143-5.
65. Altun A, Ugur-Altun B. Effects of melatonin on cardiovascular system. In: Pandi-Perumal SR, Cardinali DP, eds. Melatonin: From Molecules to Therapy, chapter 45. NewYork: Nova Science Publishers, 2006: (in press).
66. Zanoboni A, Forni A, Zanoboni-Muciaccia W, Zanussi C. Effect of pinealectomy on arterial blood pressure and food and water intake in the rat. J Endocrinol Invest 1978; 1: 125-30.
67. Holmes SW, Sugden D. The effect of melatonin on pinealectomy-induced hypertension in the rat. Br J Pharmacol 1976; 56: 360-1.
68. Nishiyama K, Yasue H, Moriyama Y et al. Acute effects of melatonin administration on cardiovascular autonomic regulation in healthy men. Am Heart J 2001; 141: E9-14.
69. Cagnacci A, Arangino S, Angiolucci M, Maschio E, Melis GB. Influences of melatonin administration on the circulation of women. Am J Physiol 1998; 274: R335-8.
70. Arangino S, Cagnacci A, Angiolucci M et al. Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am J Cardiol 1999; 83: 1417-9.
71. Lusardi P, Preti P, Savino S, Piazza E, Zoppi A, Fogari R. Effect of bedtime melatonin ingestion on blood pressure of normotensive subjects. Blood Press Monit 1997; 2: 99-103.
72. Birau N, Peterssen U, Meyer C, Gottschalk J. Hypotensive effect of melatonin in essential hypertension. IRCS Med Sci 1981; 9: 906.
73. Zaslavskaya RM, Makarova LA, Shakarova AN et al. Individualized time series-based assessment of melatonin effects on blood pressure: model for pediatricians. Neuroendocrinol Lett 2003; 24: 238-46.
74. Arendt J, Bojkowski C, Folkard S et al. Some effects of melatonin and the control of its secretion in humans. Ciba Found Symp 1985; 117: 266-83.
75. Mishima K, Okawa M, Hozumi S, Hishikawa Y. Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalized demented elderly persons. Chronobiol Int 2000; 17: 419-32.
76. Sharkey KM, Eastman CI. Melatonin phase shifts human circadian rhythms in a placebo-controlled simulated night-work study. Am J Physiol 2002; 282: R454-63.
77. Santana C, Guerrero JM, Reiter RJ, Menendez-Pelaez A. Role of postsynaptic alpha-adrenergic receptors in the beta-adrenergic stimulation of melatonin production in the Syrian hamster pineal gland in organ culture. J Pineal Res 1989; 7: 13-22.
78. McLeod SD, Cairncross KD. Preliminary evidence of a synergistic alpha1- and beta1-adrenoceptor regulation of rat pineal hydroxyindole-O- methyltranferase. Gen Comp Endocrinol 1995; 97: 283-8.
79. Arendt J, Bojkowski C, Franry C, Wright J, Marks V. Immunoassasy of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol. J Clin Endocrinol Metab 1985; 60: 1166-73.
80. Cowen PJ, Bevan JS, Gosden B, Elliott SA. Treatment with beta-adrenoceptor blockers reduces plasma melatonin concentration. Br J Clin Pharmacol 1985; 19: 258-60.
81. Brismar K, Mogensen L, Wetterberg L. Depressed melatonin secretion in patients with nightmares due to beta-adrenoceptor blocking drugs. Acta Med Scand 1987; 221: 155-8.
82. Rommel T, Demisch L. Influence of chronic beta-adrenoceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension. J Neural Transm Gen Sect 1994; 95: 39-48.
83. Stoschitzky K, Sakotnik A, Lercher P et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol 1999; 55: 111-5.
84. Zaslavskaia RM, Komarov FI, Goncharov LF, Goncharova ZF, Makarova LA. Comparative study of the effectiveness of Cozaar monotherapy and Cozaar and melatonin combined therapy in aged patients with hypertension. Klin Med (Mosk) 1998; 76: 49-51.
85. Zaslavskaia RM, Komarov FI, Shakirova AN, Teiblium MM, Akhmetov KZ. Effect of moxonidine monotherapy and in combination with melatonin on hemodynamic parameters in patients with arterial hypertension. Klin Med (Mosk) 2000; 78: 41-4.
86. Cagnacci A, Elliott JA, Yen SS. Melatonin: a major regulator of the circadian rhythm of core temperature in humans. J Clin Endocrinol Metab 1992; 75: 447-52.
87. Ahmed HH, Mannaa F, Elmegeed GA, Doss SH. Cardioprotective activity of melatonin and its novel synthesized derivatives on doxorubicin-induced cardiotoxicity. Bioorg Med Chem 2005; 13: 1847-57.
88. Sahna E, Parlakpinar H, Ozer MK, Ozturk F, Ozugurlu F, Acet A. Melatonin protects against myocardial doxorubicin toxicity in rats: role of physiological concentrations. J Pineal Res 2003; 35: 257-61.
89. Kim C, Kim N, Joo H et al. Modulation by melatonin of the cardiotoxic and antitumor activities of adriamycin. J Cardiovasc Pharmacol 2005; 46: 200-10.
90. Dziegiel P, Murawska-Cialowicz E, Jethon Z et al. Melatonin stimulates the activity of protective antioxidative enzymes in myocardial cells of rats in the course of doxorubicin intoxication. J Pineal Res 2003; 35: 183-7.
91. Paskaloglu K, Sener G, Ayangolu-Dulger G. Melatonin treatment protects against diabetes-induced functional and biochemical changes in rat aorta and corpus cavernosum. Eur J Pharmacol 2004; 499: 345-54.
92. Zaslavskaya RM, Lilitsa GV, Dilmagambetova GS et al. Melatonin, refractory hypertension, myocardial ischemia and other challenges in nightly blood pressure lowering. Biomed Pharmacother 2004; 58: S129-34.
93. O'Rourke ST, Hammad H, Delagrange P, Scalbert E, Vanhoutte PM. Melatonin inhibits nitrate tolerance in isolated coronary arteries. Br J Pharmacol 2003; 139: 1326-32.
94. Gazi S, Altun A, Erdogan O. Contrast-induced nephropathy: preventive and protective effects of melatonin. J Pineal Res 2006; 41: 53-7.
95. Szarszoi O, Asemu G, Vanecek J, Ost'adal B, Kolar F. Effects of melatonin on ischemia and reperfusion injury of the rat heart. Cardiovasc Drugs Ther 2001; 15: 251-7.
96. Lee YM, Chen HR, Hsiao G, Sheu JR, Wang JJ, Yen MH. Protective effects of melatonin on myocardial ischemia/reperfusion injury in vivo. J Pineal Res 2002; 33: 72-80.
97. Sahna E, Acet A, Ozer MK, Olmez E. Myocardial ischemia-reperfusion in rats: reduction of infarct size by either supplemental physiological or pharmacological doses of melatonin. J Pineal Res 2002; 33: 234-8.
98. Sahna E, Olmez E, Acet A. Effects of physiological and pharmacological concentrations of melatonin on ischemia-reperfusion arrhythmias in rats: can the incidence of sudden cardiac death be reduced? J Pineal Res 2002; 32: 194-8.
99. Sahna E, Parlakpinar H, Turkoz Y, Acet A. Protective effects of melatonin on myocardial ischemia reperfusion induced infarct size and oxidative changes. Physiol Res 2005; 55: 491-5.
100. Acikel M, Buyukokuroglu ME, Aksoy H, Erdogan F, Erol MK. Protective effects of melatonin against myocardial injury induced by isoproterenol in rats. J Pineal Res 2003; 35: 75-9.
101. Claustrat B, Chiquet C, Brun J, Chazot G. Melatonin, light and migraine. In: Pandi-Perumal SR, Cardinali DP, eds. Melatonin: Biological Basis of its Function in Health and Disease. Austin: Landes Bioscience, 2003: 218-23.
102. Claustrat B, Brun J, Chiquet C, Chazot G, Borson-Chazot F. Melatonin secretion is supersensitive to light in migraine. Cephalalgia 2004; 24: 128-33.
103. Pringsheim T. Cluster headache: evidence for a disorder of circadian rhythm and hypothalamic function. Can J Neurol Sci 2002; 29: 33-40.
104. Peres MF. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia 2005; 25: 403-11.
105. Beloosesky Y, Grinblat J, Laudon M, Grosman B, Streifler JY, Zisapel N. Melatonin rhythms in stroke patients. Neurosci Lett 2002; 319: 103-6.
106. Fiorina P, Lattuada G, Silvestrini C, Ponari O, Dall'Aglio P. Disruption of nocturnal melatonin rhythm and immunological involvement in ischaemic stroke patients. Scand J Immunol 1999; 50: 228-31.
107. Pang SF, Li Y, Jiang DH, Chang B, Xie BL. Acute cerebral hemorrhage changes the nocturnal surge of plasma melatonin in humans. J Pineal Res 1990; 9: 193-208.
108. Reiter RJ, Tan DX, Leon J, Kilic U, Kilic E. When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp Biol Med (Maywood) 2005; 230: 104-17.
109. Macleod MR, O'Collins T, Horky LL, Howells DW, Donnan GA. Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J Pineal Res 2005; 38: 35-41.
110. Srinivasan V, Pandi-Perumal SR, Maestroni GJ, Esquifino AI, Hardeland R, Cardinali DP. Role of melatonin in neurodegenerative diseases. Neurotox Res 2005; 7: 293-318.
111. Mayo JC, Sainz RM, Tan DX, Antolin I, Rodriguez C, Reiter RJ. Melatonin and Parkinson's disease. Endocrine 2005; 27: 169-78.
112. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res 2005; 38: 145-52.
113. Gupta M, Aneja S, Kohli K. Add-on melatonin improves quality of life in epileptic children on valproate monotherapy: a randomized, double-blind, placebo-controlled trial. Epilepsy Behav 2004; 5: 316-21.
114. Molina-Carballo A, Munoz-Hoyos A, Reiter RJ et al. Utility of high doses of melatonin as adjunctive anticonvulsant therapy in a child with severe myoclonic epilepsy: two years experience. J Pineal Res 1997; 23: 97-105.
115. Gordon N. The therapeutics of melatonin: a paediatric perspective. Brain Dev 2000; 22: 213-7.
116. Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet 1998; 351: 1254.
117. Pacchierotti C, Iapichino S, Bossini L, Pieraccini F, Castrogiovanni P. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front Neuroendocrinol 2001; 22: 18-32.
118. Claustrat B, Chazot G, Brun J, Jordan D, Sassolas G. A chronobiological study of melatonin and cortisol secretion in depressed subjects: plasma melatonin, a biochemical marker in major depression. Biol Psychiatry 1984; 19: 1215-28.
119. Voderholzer U, Laakmann G, Becker U et al. Circadian profiles of melatonin in melancholic depressed patients and healthy subjects in relation to cortisol secretion and sleep. Psychiatry Res 1997; 71: 151-61.
120. Crasson M, Kjiri S, Colin A et al. Serum melatonin and urinary 6-sulfatoxymelatonin in major depression. Psychoneuroendocrinology 2004; 29: 1-12.
121. Rabe-Jablonska J, Szymanska A. Diurnal profile of melatonin secretion in the acute phase of major depression and in remission. Med Sci Monit 2001; 7: 946-52.
122. Magnusson A, Boivin D. Seasonal affective disorder: an overview. Chronobiol Int 2003; 20: 189-207.
123. Karadottir R, Axelsson J. Melatonin secretion in SAD patients and healthy subjects matched with respect to age and sex. Int J Circumpolar Health 2001; 60: 548-51.
124. Arendt J, Bhanji S, Franey C, Mattingly D. Plasma melatonin levels in anorexia nervosa. Br J Psychiatry 1992; 161: 361-4.
125. Balan S, Leibovitz A, Zila SO et al. The relation between the clinical subtypes of delirium and the urinary level of 6-SMT. J Neuropsychiatry Clin Neurosci 2003; 15: 363-6.
126. Vijayalaxmi, Reiter RJ, Tan DX, Herman TS, Thomas CR Jr. Melatonin as a radioprotective agent: a review. Int J Radiat Oncol Biol Phys 2004; 59: 639-53.
127. Sebra MLV, Bignotto M, Pinto LR Jr, Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res 2000; 29: 193-200.
128. Jahnke G, Marr M, Myers C, Wilson R, Travlos G, Price C. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci 1999; 50: 271-9.